Skip to content
OpenCapital
Get started

Collegium Pharmaceutical, Inc. COLL Liability for cash-settled share-based awards assumed from Ironshore Acquisition

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.15B+17.9%
Enterprise value$869.67M-0.3%
P/E15.4×-6.9×
P/S1.5×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0×0.0×
Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept coll:AccruedLiabilityForCashSettledShareBasedAwardsAssumedFromAcquireeCurrent.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s liability for cash-settled share-based awards assumed from ironshore acquisition.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s liability for cash-settled share-based awards assumed from ironshore acquisition?
Collegium Pharmaceutical, Inc. (COLL) reported liability for cash-settled share-based awards assumed from ironshore acquisition of $2.44M in Q1 2026.